Cargando…
Nucleic Acid Hybrids as Advanced Antibacterial Nanocarriers
Conventional antibiotic therapy is often challenged by poor drug penetration/accumulation at infection sites and poses a significant burden to public health. Effective strategies to enhance the therapeutic efficacy of our existing arsenal include the use of nanoparticulate delivery platforms to impr...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408145/ https://www.ncbi.nlm.nih.gov/pubmed/32650506 http://dx.doi.org/10.3390/pharmaceutics12070643 |
_version_ | 1783567770250641408 |
---|---|
author | Obuobi, Sybil Škalko-Basnet, Nataša |
author_facet | Obuobi, Sybil Škalko-Basnet, Nataša |
author_sort | Obuobi, Sybil |
collection | PubMed |
description | Conventional antibiotic therapy is often challenged by poor drug penetration/accumulation at infection sites and poses a significant burden to public health. Effective strategies to enhance the therapeutic efficacy of our existing arsenal include the use of nanoparticulate delivery platforms to improve drug targeting and minimize adverse effects. However, these nanocarriers are often challenged by poor loading efficiency, rapid release and inefficient targeting. Nucleic acid hybrid nanocarriers are nucleic acid nanosystems complexed or functionalized with organic or inorganic materials. Despite their immense potential in antimicrobial therapy, they are seldom utilized against pathogenic bacteria. With the emergence of antimicrobial resistance and the associated complex interplay of factors involved in antibiotic resistance, nucleic acid hybrids represent a unique opportunity to deliver antimicrobials against resistant pathogens and to target specific genes that control virulence or resistance. This review provides an unbiased overview on fabricating strategies for nucleic acid hybrids and addresses the challenges of pristine oligonucleotide nanocarriers. We report recent applications to enhance pathogen targeting, binding and control drug release. As multifunctional next-generational antimicrobials, the challenges and prospect of these nanocarriers are included. |
format | Online Article Text |
id | pubmed-7408145 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-74081452020-08-25 Nucleic Acid Hybrids as Advanced Antibacterial Nanocarriers Obuobi, Sybil Škalko-Basnet, Nataša Pharmaceutics Review Conventional antibiotic therapy is often challenged by poor drug penetration/accumulation at infection sites and poses a significant burden to public health. Effective strategies to enhance the therapeutic efficacy of our existing arsenal include the use of nanoparticulate delivery platforms to improve drug targeting and minimize adverse effects. However, these nanocarriers are often challenged by poor loading efficiency, rapid release and inefficient targeting. Nucleic acid hybrid nanocarriers are nucleic acid nanosystems complexed or functionalized with organic or inorganic materials. Despite their immense potential in antimicrobial therapy, they are seldom utilized against pathogenic bacteria. With the emergence of antimicrobial resistance and the associated complex interplay of factors involved in antibiotic resistance, nucleic acid hybrids represent a unique opportunity to deliver antimicrobials against resistant pathogens and to target specific genes that control virulence or resistance. This review provides an unbiased overview on fabricating strategies for nucleic acid hybrids and addresses the challenges of pristine oligonucleotide nanocarriers. We report recent applications to enhance pathogen targeting, binding and control drug release. As multifunctional next-generational antimicrobials, the challenges and prospect of these nanocarriers are included. MDPI 2020-07-08 /pmc/articles/PMC7408145/ /pubmed/32650506 http://dx.doi.org/10.3390/pharmaceutics12070643 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Obuobi, Sybil Škalko-Basnet, Nataša Nucleic Acid Hybrids as Advanced Antibacterial Nanocarriers |
title | Nucleic Acid Hybrids as Advanced Antibacterial Nanocarriers |
title_full | Nucleic Acid Hybrids as Advanced Antibacterial Nanocarriers |
title_fullStr | Nucleic Acid Hybrids as Advanced Antibacterial Nanocarriers |
title_full_unstemmed | Nucleic Acid Hybrids as Advanced Antibacterial Nanocarriers |
title_short | Nucleic Acid Hybrids as Advanced Antibacterial Nanocarriers |
title_sort | nucleic acid hybrids as advanced antibacterial nanocarriers |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408145/ https://www.ncbi.nlm.nih.gov/pubmed/32650506 http://dx.doi.org/10.3390/pharmaceutics12070643 |
work_keys_str_mv | AT obuobisybil nucleicacidhybridsasadvancedantibacterialnanocarriers AT skalkobasnetnatasa nucleicacidhybridsasadvancedantibacterialnanocarriers |